273 related articles for article (PubMed ID: 35641493)
21. Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.
Bothwell PJ; Kron CD; Wittke EF; Czerniak BN; Bode BP
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30029480
[TBL] [Abstract][Full Text] [Related]
22. NEDD4L downregulates autophagy and cell growth by modulating ULK1 and a glutamine transporter.
Lee DE; Yoo JE; Kim J; Kim S; Kim S; Lee H; Cheong H
Cell Death Dis; 2020 Jan; 11(1):38. PubMed ID: 31959741
[TBL] [Abstract][Full Text] [Related]
23. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D
J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158
[TBL] [Abstract][Full Text] [Related]
24. ASC amino acid transporter 2, defined by enzyme-mediated activation of radical sources, enhances malignancy of GD2-positive small-cell lung cancer.
Esaki N; Ohkawa Y; Hashimoto N; Tsuda Y; Ohmi Y; Bhuiyan RH; Kotani N; Honke K; Enomoto A; Takahashi M; Furukawa K; Furukawa K
Cancer Sci; 2018 Jan; 109(1):141-153. PubMed ID: 29151270
[TBL] [Abstract][Full Text] [Related]
25. CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling.
Jin X; Shi Q; Li Q; Zhou L; Wang J; Jiang L; Zhao X; Feng K; Lin T; Lin Z; Zhuang H; Yang J; Hu C; Zhang L; Shen L; Lu Y; Zhu J; Wang H; Qi H; Meng X; Xi Y; Pan J; Fang S; Tian H; Zhou C; Zhang P; Gao K; Zhao SM; Li Y; Gong Z; Wang C
Leukemia; 2020 May; 34(5):1305-1314. PubMed ID: 31776466
[TBL] [Abstract][Full Text] [Related]
26. Inducible antisense RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells.
Fuchs BC; Perez JC; Suetterlin JE; Chaudhry SB; Bode BP
Am J Physiol Gastrointest Liver Physiol; 2004 Mar; 286(3):G467-78. PubMed ID: 14563674
[TBL] [Abstract][Full Text] [Related]
27. NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence
Ding M; Bu X; Li Z; Xu H; Feng L; Hu J; Wei X; Gao J; Tao Y; Cai B; Liu Y; Qu X; Shen L
Int J Biol Sci; 2020; 16(16):3100-3115. PubMed ID: 33162818
[No Abstract] [Full Text] [Related]
28. Progesterone inhibits endometrial cancer growth by inhibiting glutamine metabolism through ASCT2.
Guo J; Fan J; Zhang Y; Li M; Jin Z; Shang Y; Zhang H; Kong Y
Biosci Rep; 2024 Mar; 44(3):. PubMed ID: 38415405
[TBL] [Abstract][Full Text] [Related]
29. Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.
Bröer A; Rahimi F; Bröer S
J Biol Chem; 2016 Jun; 291(25):13194-205. PubMed ID: 27129276
[TBL] [Abstract][Full Text] [Related]
30. The role of the glutamine transporter ASCT2 in antineoplastic therapy.
Teixeira E; Silva C; Martel F
Cancer Chemother Pharmacol; 2021 Apr; 87(4):447-464. PubMed ID: 33464409
[TBL] [Abstract][Full Text] [Related]
31. Targeting glutamine transport to suppress melanoma cell growth.
Wang Q; Beaumont KA; Otte NJ; Font J; Bailey CG; van Geldermalsen M; Sharp DM; Tiffen JC; Ryan RM; Jormakka M; Haass NK; Rasko JE; Holst J
Int J Cancer; 2014 Sep; 135(5):1060-71. PubMed ID: 24531984
[TBL] [Abstract][Full Text] [Related]
32. Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Tan Y; Ci Y; Dai X; Wu F; Guo J; Liu D; North BJ; Huo J; Zhang J
Oncotarget; 2017 Jul; 8(29):47890-47901. PubMed ID: 28599312
[TBL] [Abstract][Full Text] [Related]
33. The role of ASCT2 in cancer: A review.
Liu Y; Zhao T; Li Z; Wang L; Yuan S; Sun L
Eur J Pharmacol; 2018 Oct; 837():81-87. PubMed ID: 30025811
[TBL] [Abstract][Full Text] [Related]
34. 2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport.
Schulte ML; Khodadadi AB; Cuthbertson ML; Smith JA; Manning HC
Bioorg Med Chem Lett; 2016 Feb; 26(3):1044-1047. PubMed ID: 26750251
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
36. Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5.
Wang C; Wu J; Wang Z; Yang Z; Li Z; Deng H; Li L; Peng X; Feng M
Biomaterials; 2018 Nov; 183():77-92. PubMed ID: 30149232
[TBL] [Abstract][Full Text] [Related]
37. Glutamine availability up-regulates expression of the amino acid transporter protein ASCT2 in HepG2 cells and stimulates the ASCT2 promoter.
Bungard CI; McGivan JD
Biochem J; 2004 Aug; 382(Pt 1):27-32. PubMed ID: 15175006
[TBL] [Abstract][Full Text] [Related]
38. Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation.
Yu X; Plotnikova O; Bonin PD; Subashi TA; McLellan TJ; Dumlao D; Che Y; Dong YY; Carpenter EP; West GM; Qiu X; Culp JS; Han S
Elife; 2019 Oct; 8():. PubMed ID: 31580259
[TBL] [Abstract][Full Text] [Related]
39. Rational design of ASCT2 inhibitors using an integrated experimental-computational approach.
Garibsingh RA; Ndaru E; Garaeva AA; Shi Y; Zielewicz L; Zakrepine P; Bonomi M; Slotboom DJ; Paulino C; Grewer C; Schlessinger A
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507995
[TBL] [Abstract][Full Text] [Related]
40. Publisher Correction: Neddylation inhibition induces glutamine uptake and metabolism by targeting CRL3
Zhou Q; Lin W; Wang C; Sun F; Ju S; Chen Q; Wang Y; Chen Y; Li H; Wang L; Hu Z; Jin H; Wang X; Sun Y
Nat Commun; 2022 Jun; 13(1):3424. PubMed ID: 35701438
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
